Live
FierceBiotechAlcon, Lensar drop $356M acquisition deal after black eye from FTCFierceBiotechFDA rejects Aldeyra dry eye disease drug for 3rd time, citing inconsistent study findingsFierceBiotechHitting regulatory roadblock, Bicycle pumps brakes on lead program and deflates headcount by 30%FierceBiotechJ&J changes New York state of mind, closing JLABS site after 8 yearsPromega BlogSome St. Patrick’s Day Science: Green Rivers, Four-Leaf Clovers and Optics of a Good PintBioPharma DivePfizer’s Ibrance successor moves forward with new study dataBioWorldG2gbio secures license deal, ₩20B investment from Samsung EpisBioWorldSamsung is adding trials and EHR access to Galaxy devicesBioWorldKanaph, Imbiologics to kick off 2026 Korea biotech, med-tech IPOsBioWorldKanaph’s $27M IPO to aid multi-modality cancer, immune portfolioBioWorldImmutep stock plummets 90% on efti phase III failure in NSCLCEndpoints NewsPfizer's next-gen breast cancer data; Bristol Myers' PRMT5 candidate
BioWorld Mar 17, 2026

Immutep stock plummets 90% on efti phase III failure in NSCLC

Immutep stock plummets 90% on efti phase III failure in NSCLC

Original
Body unavailable. Use the original source.

Directory

59 All